Brief: Strides Pharma Science Receives USFDA Approval For Sucralfate Oral Suspension, 1Gm/10Ml
22/05/2024 06:38
May 22 (Reuters) - Strides Pharma Science Ltd SRID.NS :
* RECEIVES USFDA APPROVAL FOR SUCRALFATE ORAL SUSPENSION,
1GM/10ML
* CO HAS SET TARGET TO LAUNCH ABOUT 60 NEW PRODUCTS OVER
THREE
YEARS IN US
Source text for Eikon: ID:nBSEkpNnl
Further company coverage: SRID.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Strides Pharma Science
See all newsIndia's Strides Pharma jumps on successful closure of USFDA inspection at Bengaluru facility
Brief: Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru
Brief: Strides Pharma Science Receives US FDA Establishment Inspection Report For Bengaluru Facility
Brief: Strides Pharma Science June-Quarter Consol Net Profit 1.57 Billion Rupees
Brief: Strides Pharma Science March-Quarter Consol Net Profit 1.27 Billion Rupees